Back
  • Albania Albania
  • Argentina Argentina
  • Australia Australia
  • Austria Austria
  • Belarus Belarus
  • Belgium Belgium
  • Brazil Brazil
  • Bulgaria Bulgaria
  • Canada Canada
  • Chile Chile
  • China China
  • Colombia Colombia
  • Costa Rica Costa Rica
  • Croatia Croatia
  • Czech Republic Czech Republic
  • Denmark Denmark
  • Egypt Egypt
  • Estonia Estonia
  • Finland Finland
  • France France
  • Georgia Georgia
  • Germany Germany
  • Greece Greece
  • Hong Kong Hong Kong
  • Hungary Hungary
  • India India
  • Indonesia Indonesia
  • Ireland Ireland
  • Israel Israel
  • Italy Italy
  • Japan Japan
  • Kazakhstan Kazakhstan
  • Korea Korea
  • Latvia Latvia
  • Lithuania Lithuania
  • Luxembourg Luxembourg
  • Mexico Mexico
  • Montenegro Montenegro
  • Morocco Morocco
  • Myanmar Myanmar
  • Netherlands Netherlands
  • New Zealand New Zealand
  • Norway Norway
  • Pakistan Pakistan
  • Panama Panama
  • Peru Peru
  • Philippines Philippines
  • Poland Poland
  • Portugal Portugal
  • Qatar Qatar
  • Romania Romania
  • Russia Russia
  • Saudi Arabia Saudi Arabia
  • Serbia Serbia
  • Singapore Singapore
  • Slovakia Slovakia
  • South Africa South Africa
  • Spain Spain
  • Sweden Sweden
  • Taiwan Taiwan
  • Thailand Thailand
  • Turkey Turkey
  • Ukraine Ukraine
  • United Arab Emirates United Arab Emirates
  • United Kingdom United Kingdom
  • United States United States
  • Vietnam Vietnam

Disruption 2020 - Q3 Lab Update

Author: Aaron Jodka

By Aaron Jodka | October 2020

Greater Boston’s life science market is bucking the trends of the area’s office market. Absorption is positive, active tenant requirements are rebounding, and investors want a piece of the action. Here are six takeaways on the third quarter’s lab market:

  • Disruption2020_Lifescience-Deals-ImageLab vacancies fell in the third quarter, to 6.7% across Greater Boston, while office rose to 15.5%.

  • This marks 14 straight quarters of positive lab absorption; year-to-date, it is nearly 700,000 SF.

  • Major deals by Bristol-Myers Squibb (360,000 SF) and CRISPR (263,000 SF) demonstrate the strength of the lab market.

  • Vacancies got even lower in East Cambridge (0.3%).

  • Manufacturing requirements are picking up — challenged by the few existing plug-and-play options today.

  • Investors are clamoring to get into this market, while those already here are expanding their holdings.


     

Subscribe to Colliers In Focus Blog Posts